CTS-Clinical and Translational Science

Papers
(The H4-Index of CTS-Clinical and Translational Science is 31. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Precision Medicine, AI, and the Future of Personalized Health Care335
COVID‐19 vaccine hesitancy: Race/ethnicity, trust, and fear230
Clinical and Autoimmune Characteristics of Severe and Critical Cases of COVID‐19220
Safety, Tolerability, and Pharmacokinetics of Remdesivir, An Antiviral for Treatment of COVID‐19, in Healthy Subjects171
COVID‐19 and Immunological Dysregulation: Can Autoantibodies be Useful?113
SARS‐CoV‐2 infection as a trigger of autoimmune response93
The Potential of Low Molecular Weight Heparin to Mitigate Cytokine Storm in Severe COVID‐19 Patients: A Retrospective Cohort Study87
Evolving Role for Pharmacotherapy in NAFLD/NASH81
3D cell culture models: Drug pharmacokinetics, safety assessment, and regulatory consideration74
What Do We Know About Remdesivir Drug Interactions?67
Pharmacokinetics of Favipiravir in Critically Ill Patients With COVID‐1961
Opportunities and challenges in translational science55
Clinical Trial Generalizability Assessment in the Big Data Era: A Review51
Characterizing the reproducibility in using a liver microphysiological system for assaying drug toxicity, metabolism, and accumulation45
COVID‐19 and Venous Thromboembolism in Intensive Care or Medical Ward44
Remote Monitoring in Clinical Trials During the COVID‐19 Pandemic44
Pharmacogenomics Biomarker Discovery and Validation for Translation in Clinical Practice41
First‐in‐human study of milvexian, an oral, direct, small molecule factor XIa inhibitor41
Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial41
Risk Assessment of Drug‐Induced Long QT Syndrome for Some COVID‐19 Repurposed Drugs38
Pharmacogenomics in Asian Subpopulations and Impacts on Commonly Prescribed Medications38
An Evaluation of Biometric Monitoring Technologies for Vital Signs in the Era of COVID‐1938
Risk of Metformin in Patients With Type 2 Diabetes With COVID‐19: A Preliminary Retrospective Report38
Biolink Model: A universal schema for knowledge graphs in clinical, biomedical, and translational science36
Approval success rates of drug candidates based on target, action, modality, application, and their combinations35
CYP2C19 Allele Frequencies in Over 2.2 Million Direct‐to‐Consumer Genetics Research Participants and the Potential Implication for Prescriptions in a Large Health System34
Effect of Combination Therapy of Hydroxychloroquine and Azithromycin on Mortality in Patients With COVID‐1934
Effect of selenium on thyroid autoimmunity and regulatory T cells in patients with Hashimoto’s thyroiditis: A prospective randomized‐controlled trial33
CYP2C9 and CYP2C19: Deep Mutational Scanning and Functional Characterization of Genomic Missense Variants32
Hydroxychloroquine for Treatment of SARS‐CoV‐2 Infection? Improving Our Confidence in a Model‐Based Approach to Dose Selection31
Bromhexine Hydrochloride Tablets for the Treatment of Moderate COVID‐19: An Open‐Label Randomized Controlled Pilot Study31
0.11197710037231